PUBLISHER: DelveInsight | PRODUCT CODE: 1462304
PUBLISHER: DelveInsight | PRODUCT CODE: 1462304
"Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about nemvaleukin alfa for ovarian cancer in the seven major markets. A detailed picture of the nemvaleukin alfa for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the nemvaleukin alfa for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the nemvaleukin alfa market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Nemvaleukin alfa (previously known as ALKS 4230) is an interleukin-2 receptor agonist being developed by Alkermes for the treatment of solid tumors, including head and neck cancer, small cell lung cancer, ovarian cancer, fallopian tube cancer, and others. It is a fusion protein consisting of modified IL-2 and the high-affinity IL-2 alpha receptor chain. This combination is designed to expand tumor-destroying immune cells while not activating immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The agent's selectivity is meant to mitigate limitations while boosting the anti-tumor effects of IL-2 therapy.
It is currently being investigated in Phase III clinical trial (ARTISTRY-7) for the potential treatment of Platinum-resistant Ovarian Cancer that is estimated to be completed by December 2025.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Nemvaleukin alfa Analytical Perspective by DelveInsight
This report provides a detailed market assessment of nemvaleukin alfa for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of nemvaleukin alfa for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.